Zepbound Constipation: SURMOUNT-1 Rates, Mechanism & Evidence-Based Relief Protocol

Constipation is one of the most common GI side effects on Zepbound after nausea and diarrhea. The SURMOUNT-1 pivotal trial of tirzepatide for chronic weight management reported constipation in 11.7% of patients on the 15 mg dose vs. 5.8% on placebo over 72 weeks^[2]. The mechanism is the same one that suppresses appetite: tirzepatide’s dual GIP + GLP-1 receptor activation slows gastric emptying and reduces overall GI motility, with a more profound deceleration than single-agonist GLP-1 drugs^[6]. This guide covers what the SURMOUNT trials and the Zepbound FDA label actually report, when constipation peaks and resolves, the evidence-based relief protocol, and the red-flag warning signs that mean stop self-managing and call your prescriber immediately.

The honest short answer

If you’re titrating up on Zepbound and bowel movements have gone from daily to every 3-4 days, that’s the textbook tirzepatide pattern. SURMOUNT-1 reported constipation in 6.8% on 5 mg, 6.4% on 10 mg, and 11.7% on 15 mg vs. 5.8% on placebo over 72 weeks of treatment^[2]. The dose-response is real: the 15 mg dose produces roughly double the placebo rate. For most patients this resolves with a deliberate fiber-fluid-walking protocol layered on from day one of titration, not improvised in week six when you’re already miserable. The red flag — no stool for 5+ days plus abdominal pain or vomiting — warrants an immediate call to your prescriber, not another laxative.

What SURMOUNT-1 and SURMOUNT-4 actually measured

SURMOUNT-1 was the 72-week pivotal phase 3 trial of tirzepatide for chronic weight management in 2,539 adults with obesity or overweight plus comorbidities. The Jastreboff 2022 NEJM publication reported the constipation adverse-event rates by dose in the safety table^[2]:

• Tirzepatide 5 mg — 6.8% constipation.
• Tirzepatide 10 mg — 6.4% constipation.
• Tirzepatide 15 mg — 11.7% constipation (the highest-dose Zepbound maintenance level).
• Placebo arm — 5.8% constipation as the background rate.

SURMOUNT-4 extended the question into maintenance: after 36 weeks of open-label tirzepatide lead-in, patients were randomized to continued tirzepatide or switched to placebo for an additional 52 weeks. Constipation continued to be reported on the active arm at rates consistent with the SURMOUNT-1 maintenance phase, while the switch-to-placebo arm showed the expected resolution of GI adverse events as the drug washed out^[3]. The implication is the same one we see in STEP-4 for semaglutide: tirzepatide’s motility effect persists as long as you remain on the drug, so the constipation-management habits need to be permanent, not time-limited.

The Zepbound FDA label Section 6.1 pools the constipation rates across the registration trials and reports figures consistent with SURMOUNT-1^[1]. Tirzepatide’s GI side-effect profile broadly resembles the GLP-1 class but with the dual-agonist mechanism producing slightly different proportions: more diarrhea, comparable nausea, and comparable to slightly higher constipation at the top dose vs. semaglutide weight-loss dosing.

Why Zepbound causes constipation (dual GIP + GLP-1 slows gastric emptying)

Tirzepatide is a unimolecular dual agonist of the GIP and GLP-1 receptors. Activation of GLP-1 receptors on enteric neurons slows gastric emptying and reduces overall gut motility — the same mechanism that produces the satiety effect responsible for weight loss^[6]. Marathe and colleagues’ 2013 review in Peptides summarized the physiology: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon^[6]. The added GIP agonism in tirzepatide compounds the motility effect; pharmacokinetic studies of tirzepatide document more profound gastric-emptying delay than equivalent semaglutide exposure, particularly during dose titration.

In practical terms: food sits in the stomach longer, the small bowel moves contents along more slowly, and the colon has more time to reabsorb water from stool. Drier stool plus slower transit equals the textbook recipe for constipation. The same mechanism that helps you eat less also helps you go less often. For the head-to-head comparison of tirzepatide vs. semaglutide on weight outcomes and GI tolerability, see our tirzepatide vs. semaglutide head-to-head guide.

Three additional factors stack on top of the direct motility effect:

• Lower food volume — eating less means less fiber and less stool bulk. A 1,200-calorie day with no deliberate fiber focus often delivers under 10g of fiber, well below the 25-35g/day adult target^[7].
• Lower fluid intake — satiety on a GLP-1 extends to thirst for many patients. Sipping water all day takes conscious effort once the prompt-to-drink-with-meals is gone.
• Concurrent antiemetics — if you’re using ondansetron (Zofran) for nausea, that drug itself causes constipation, and the two effects stack badly. See our nausea management guide for the antiemetic trade-off discussion.

When Zepbound constipation peaks and resolves

Unlike nausea, which is concentrated in the first 1-2 weeks after each dose step, constipation has a different temporal pattern. In SURMOUNT-1 and SURMOUNT-4, GI adverse events were reported as cumulative incidences over the 72-week treatment periods, with constipation building gradually rather than spiking around each titration^[2][3]. The pattern most prescribers see in practice:

• Weeks 1-4 (titration to 2.5 or 5 mg) — constipation builds gradually as gut transit slows and food/fluid intake drops. Many patients don’t notice until they realize they haven’t had a bowel movement in 3-4 days.
• Weeks 4-12 (titration through 7.5 and 10 mg) — constipation often peaks during this window. Hard, dry stools and infrequent bowel movements (every 3-5 days) are the typical report, especially at the 10 mg step.
• Months 3-6 (titration to 12.5 or 15 mg maintenance) — the gut adapts to the slowed motility for most patients. Many report bowel habits stabilizing at a new normal — less frequent than baseline but more predictable. A subset of patients on the 15 mg dose experience persistent constipation through year one.
• Long-term maintenance — SURMOUNT-4 reported that GI adverse events including constipation continued at low rates through the continued-tirzepatide arm vs. a clear drop after switching to placebo, suggesting the motility effect persists as long as you’re on the drug^[3].

The takeaway: don’t wait until you’re miserable. Start the fiber, fluid, and walking habits from day one of titration, not after week four when you’re already struggling. For the full side-effect timeline by drug and week, our GLP-1 side effect timeline tool renders the SURMOUNT-1 + STEP-1 data interactively.

Practical relief protocol: fiber, fluids, walking

The first-line relief protocol is conservative and well-supported. It costs nothing, has no drug interactions, and is what most gastroenterologists recommend before any laxative.

Soluble fiber 25-35g/day

Anderson and colleagues’ comprehensive 2009 Nutrition Reviews synthesis documented that dietary fiber consumption above the 25-35g/day adult target improves stool frequency, softness, and transit time, with soluble fiber (psyllium, oat beta-glucan, fruit pectin) showing the most consistent effect on constipation^[7]. On a 1,200-1,500 calorie Zepbound day, hitting 25-35g of fiber requires deliberate planning — you cannot get there by accident on a typical Western reduced-calorie diet.

• Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1-3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation.
• Ground flaxseed — 1-2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
• Chia seeds — 1-2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
• High-fiber whole foods — raspberries (8g per cup), pears with skin (5-6g each), avocado (10g each), lentils (15g per cup cooked), black beans (15g per cup), bran cereal (10g+ per serving).

Use our GLP-1 fiber calculator to plan a day that actually hits 25-35g; without planning, most Zepbound patients land between 8-12g.

Hydration 2.5-3L/day

Fiber without enough fluid is a worse outcome than no fiber. Insoluble fiber needs water to soften stool; soluble fiber needs water to form the gel that lubricates transit. The standard recommendation for an adult on a GLP-1 is 2.5-3 liters of non-caffeinated fluid per day — this is also the volume that protects against the FDA-label acute kidney injury risk (see What NOT to do below)^[1].

Practical patterns that work:

• A 24 oz water bottle next to you all day, refilled three times (totals ~2.1L).
• A full 8 oz glass with each medication or supplement.
• Herbal tea or sparkling water counts toward fluid totals. Coffee counts but is mildly dehydrating at high doses; the net is still positive for most people.

Walking and gentle movement

Physical activity stimulates colonic motility. A 20-30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. The morning is particularly effective because the gastrocolic reflex (colon waking up after the first meal of the day) is the strongest intrinsic peristaltic signal you have.

Pelvic-floor mechanics matter too. Squatting (or using a footstool like a Squatty Potty under the feet during a bowel movement) changes the anorectal angle and reduces the straining required — particularly helpful when stool is harder than usual on tirzepatide.

Second-line: magnesium citrate, osmotic laxatives, stool softeners

If the first-line measures aren’t enough after 7-10 days of consistent effort, second-line options are appropriate. Discuss with your prescriber before starting anything if you have kidney disease, heart failure, or are on multiple other medications.

Magnesium citrate 200-400 mg

Magnesium acts as an osmotic laxative in the colon — it pulls water into the bowel lumen, softening stool and accelerating transit. Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days^[8]. Magnesium citrate is the better-absorbed form for daily use; magnesium oxide is the form studied in the Mori RCT.

• Starting dose — 200 mg magnesium citrate at bedtime. Titrate up to 400 mg if needed and tolerated.
• Side effects — loose stools or diarrhea if you overshoot. Drop the dose if this happens.
• Contraindications — kidney disease (CKD stage 3+), since impaired kidneys can’t excrete excess magnesium. Check with your prescriber if you have any renal impairment.

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.

Stool softeners (docusate)

Docusate is less effective than osmotic laxatives in randomized trials but can help if your main issue is hard, dry stool rather than infrequency. 100 mg twice daily is the standard dose.

Stimulant laxatives (senna, bisacodyl) — short-term only

Stimulant laxatives work but should be used sparingly — nightly use over weeks-months can lead to dependence in some patients. Reasonable as a 2-3 night rescue when other measures haven’t produced a bowel movement in 4-5 days. Not a long-term strategy.

Red flags: when to call your prescriber

The Zepbound FDA label was updated to include ileus as a postmarketing adverse reaction reported in patients on tirzepatide, consistent with the class effect documented for semaglutide^[1]. Ileus — the functional shutdown of normal bowel peristalsis — can mimic ordinary tirzepatide constipation in its early presentation but progresses to a medical emergency. The distinguishing features:

• No bowel movement for 5+ days AND no passage of gas (this is the cardinal sign — obstipation is more concerning than just constipation).
• Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
• Severe abdominal pain, especially crampy or colicky pain in waves.
• Vomiting, particularly vomiting of bile (green/ yellow) or feculent (foul-smelling, dark) material.
• Inability to keep down fluids.

Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your medication or the label so the treating team knows you’re on tirzepatide. Ileus and bowel obstruction can require nasogastric decompression, IV fluids, and in severe cases surgical intervention. The condition is uncommon but the consequences of missing it are serious.

For the broader differential between ileus, gastroparesis, and ordinary GLP-1 delayed emptying, see our GLP-1 side effects: what trials actually showed article. Pancreatitis (Zepbound FDA label Section 5.4) is another rare but serious consideration that overlaps with severe GI symptoms^[1]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom.

How tirzepatide compares to semaglutide on constipation

Patients often ask whether switching from Wegovy to Zepbound (or vice versa) will help with constipation. The trial data argue that constipation is a class effect and that switching molecules is unlikely to be the answer for most patients:

• Tirzepatide 15 mg (SURMOUNT-1) — 11.7% constipation over 72 weeks vs. 5.8% placebo^[2].
• Semaglutide 2.4 mg (STEP-1) — approximately 24% constipation over 68 weeks vs. 11% placebo^[4].
• Semaglutide 1 mg for diabetes (SUSTAIN-1) — approximately 5% over 30 weeks^[5].

On the face of these numbers, tirzepatide at the top weight-loss dose actually reports lower constipation incidence than semaglutide at the top weight-loss dose — 11.7% vs. 24%. Two caveats apply. First, the trials measured constipation as patient-reported AEs with different prompts and adjudication, so the comparison is not head-to-head and the absolute numbers should be read as order-of-magnitude rather than precise. Second, the GI side-effect mix differs between the two drugs: tirzepatide trends toward more diarrhea and somewhat less constipation than semaglutide at comparable weight-loss exposure. The SURMOUNT-5 head-to-head trial comparing tirzepatide vs. semaglutide directly is the definitive comparison; see our tirzepatide vs. semaglutide head-to-head article for the trial-by-trial weight-outcome and tolerability breakdown.

For patients already weighing a switch, the practical implication: if your dominant problem on semaglutide is constipation, tirzepatide may offer modest relief but at the cost of higher diarrhea risk; the better lever is usually the fiber-fluid-magnesium protocol on whichever drug you’re already on. See our Zepbound vs. Wegovy side-effects comparison for the full side-by-side.

What NOT to do (FDA dehydration + AKI warning)

The Zepbound FDA label Section 5.6 contains an explicit warning about acute kidney injury^[1]: postmarketing reports document AKI — sometimes requiring hemodialysis — in patients on tirzepatide, frequently associated with the dehydration that follows persistent nausea, vomiting, diarrhea, or reduced fluid intake. The label specifically instructs prescribers to advise patients on hydration and to monitor renal function when starting or escalating the drug.

Implications for constipation management:

• Don’t megadose osmotic laxatives. A double or triple dose of PEG 3350 or magnesium citrate can induce diarrhea, which combined with reduced GLP-1-driven thirst can drive you into the dehydration-AKI zone the FDA label warns about. Use the recommended doses and titrate gradually.
• Don’t use bowel preps as constipation treatment. A polyethylene glycol bowel prep (4 liters of GoLYTELY or similar) is designed to empty the colon for colonoscopy — it’s not a constipation remedy. The fluid shift is dangerous in a dehydrated patient.
• Don’t skip fluids to “reduce bloating” . Some patients try to fight the bloating component of constipation by drinking less. This is exactly backward and is the fastest path to AKI.
• Don’t add high-dose magnesium if you have kidney disease. CKD stage 3+ patients can develop hypermagnesemia (toxic blood magnesium levels) from oral supplements that healthy kidneys would excrete. Confirm with your prescriber.
• Don’t take stimulant laxatives nightly for weeks. Dependence is a real outcome with chronic stimulant use. Use them as a 2-3 night rescue, not a daily habit.
• Don’t ignore the ileus red flags. The most dangerous mistake is assuming “it’s just my Zepbound constipation” when the pattern has shifted to obstipation, distension, and vomiting. When in doubt, call.

Related research and tools

• Ozempic constipation: causes, FDA-label rates, and evidence-based relief — the sister article for semaglutide, covering STEP-1 and SUSTAIN-1 rates and the dose-response by drug
• Tirzepatide diarrhea: mechanism and management — the other dominant GI side effect on Zepbound, with the dual-agonist mechanism and management protocol
• Tirzepatide vs. semaglutide: head-to-head — the trial-by-trial weight outcome and GI tolerability comparison
• Zepbound vs. Wegovy side-effects comparison — the side-by-side adverse-event tables from SURMOUNT-1 and STEP-1
• GLP-1 side effects: what the trials actually showed — the comprehensive trial-by-trial side-effect table
• GLP-1 side effect questions answered — the Q&A hub with every common patient question
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week
• GLP-1 fiber calculator — plan a 25-35g/day fiber target on a reduced-calorie Zepbound day

Important disclaimer. This article is educational and does not constitute medical advice. Constipation management decisions should always be made with your prescribing clinician, particularly if you have chronic kidney disease, heart failure, or are taking multiple other medications. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.